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The emergence of resistance to antimicrobial agents is
becoming a major public health problem worldwide,
especially in hospital-acquired infections. Infectious diseases
experts are particularly concerned because organisms
resistant to available antimicrobial drugs have been isolated
in hospitals worldwide. The extent of antimicrobial-drug
resistance in developing countries, where inappropriate
antimicrobial usage may be more common, is unknown (1-6).
The emergence and spread of these multidrug-resistant
pathogens demonstrate that the medical community
(including laboratories) may have difficulty isolating and
identifying these organisms and that infection control
interventions are either not implemented, ineffective, or
implemented so late that the organism(s) has become
endemic; in these circumstances, infection control strategies
are not effective, and transmission continues (7,8).
The emergence of infections caused by methicillin-
resistant  Staphylococcus aureus (MRSA) vividly demon-
strates this failure in infection control. MRSA emerged in
Europe nearly 35 years ago concomitantly with the
introduction of methicillin; subsequently, during the mid-
1980s, epidemic strains spread in hospitals throughout the
world. In many hospitals, few, if any, infection control
precautions were implemented until recently, by which time
these strains had become endemic, with infection rates
approaching one per 100 admissions (9-12). The large
reservoir of MRSA-colonized or -infected patients at these
hospitals complicates infection control interventions.
Epidemiologic studies on antimicrobial resistance have
alerted the medical and public health communities about the
importance of emergence of antimicrobial resistance.
However, most data on antimicrobial-resistant pathogens
were collected as part of studies sponsored by the
pharmaceutical industry, and most of the studies were
methodologically flawed; thus, the data were not useful for
generalizations about antimicrobial resistance in hospitals.
In addition, in many countries, a close interrelationship does
not exist between the laboratory identifying multidrug-
resistant pathogens and the infection control personnel
responsible for the prevention and control of transmission of
such isolates. Furthermore, many laboratory-based surveil-
lance systems are designed for making patient treatment
decisions; the data are not organized in a way that can be used
to design and implement control and prevention interventions.
With the development of the Emerging Infections Plan at
the Centers for Disease Control and Prevention (CDC) and the
endorsement and adaptation of this plan by the World Health
Organization (WHO), the emergence of antimicrobial
resistance has become a public health priority (13,14). Public
health authorities in the United States and Europe realize
that the emergence of antimicrobial-drug resistance is a
global problem; no country is spared, and resistant organisms
emerging in one country are likely to spread to other
countries. With increasing travel and patient movement
throughout the world, the situation exists for transmission of
multidrug-resistant pathogens from one country or continent
to another (15-19).
Because of the urgent need for infection control
interventions to prevent further emergence of antimicrobial
drug-resistant strains and for a rapid distribution of
information about emerging organisms, we initiated the
International Network for the Study and Prevention of
Emerging Antimicrobial Resistance (INSPEAR). The main
objectives of INSPEAR are to serve as an early warning
system for emerging resistant pathogens, to facilitate rapid
distribution of information about emerging multidrug-
resistant pathogens to hospitals and public health authorities
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worldwide, and to serve as a model for the development and
implementation of infection control interventions to prevent
the emergence or transmission of antimicrobial drug-
resistant pathogens in health-care facilities. Another
important function of INSPEAR is to assist microbiologists
and infection control personnel in hospitals and countries
that lack the expertise needed to conduct microbiologic or
epidemiologic studies.
Background
INSPEAR was begun as a collaborative effort between
the Hospital Infections Program (CDC) and microbiologists
and hospital epidemiologists in the United States and
Europe. It is now a consortium of clinical microbiologists,
hospital epidemiologists, infectious diseases specialists;
experts in the fields of antimicrobial resistance, hospital
epidemiology, and computer sciences; public health agencies;
and national reference laboratories. One hundred sixty
health-care facilities in 40 countries have joined INSPEAR,
with 50% of participants in Western Europe and 29% in
Eastern Europe.
Recent Activities
Since its initiation in 1998, INSPEAR has conducted
several activities essential to the implementation of the early
warning system, such as the assessment of the way INSPEAR
centers diagnose, conduct surveillance, and control infections
caused by multidrug-resistant pathogens, as well as
proficiency testing to ensure quality testing in laboratories
participating in the program.
An assessment of MRSA infections, performed in 90
centers, was designed to assess the methods used by
bacteriology laboratories to identify S. aureus, to determine
the susceptibility of S. aureus to antimicrobial drugs, and to
assess the surveillance and infection control programs in
INSPEAR centers. This study revealed many deficiencies:
Isolation of vancomycin- and teicoplanin-resistant S. aureus
was reported by three centers but was not confirmed, and
public health authorities were not alerted. Of the laboratories
surveyed, 11% used oxacillin disks with antimicrobial content
different from that recommended by the National Committee
for Clinical Laboratory Standards or the Comité de
L’Antibiogramme de la Société Française de Microbiologie;
20% did not have an internal quality control program; 36% did
not participate in external quality control programs; and 14%
did not determine MRSA susceptibility to vancomycin. Of the
health-care facilities surveyed, 77% reported surveillance
activities; however, only 36.5% determined the incidence rate
per admission, and only 23% determined the rate per patient-
days; 40% of the facilities did not have an MRSA control
program; and 54% did not monitor or control the use of
antimicrobial drugs. These data clearly demonstrate the
urgent need to strengthen the laboratory and epidemiologic
capacities of INSPEAR centers.
A proficiency testing study was performed to investigate
the ability of INSPEAR centers to detect clinically important
resistance phenotypes, to assist centers in establishing
reliable methods to detect particular resistances, to validate
data from hospital laboratories participating in INSPEAR,
and to ensure consistent quality testing in INSPEAR clinical
laboratories. Five strains were sent to the 116 participating
laboratories: MRSA, hyper-beta-lactamase producing strain
of  S. aureus, glycopeptide-intermediate Staphylococcus
epidermidis, and van A and  van B  Enterococcus faecalis.
Seventy-six laboratories responded. Most laboratories did
well with both S. aureus challenges; however, 60 (79%) had
difficulty detecting reduced susceptibility to glycopeptides in
staphylococci. All laboratories testing van A  E. faecalis
identified it correctly as vancomycin resistant, but the results
for  van B E. faecalis varied. Thirty-nine (52%) of 75
laboratories reported susceptible results for vancomycin, but
19% misidentified van B E. faecalis as vancomycin resistant.
An assessment is being conducted to determine if participants
have modified their testing methods based on the results of
the proficiency testing and CDC recommendations.
Early Warning System
Another reason antimicrobial resistance is uncontrolled
is that clinical microbiology laboratories and the medical
community often are not aware of emerging resistance and
therefore are not prepared. Preparedness implies that
potentially emerging events be known, that laboratorians
have the capacity to detect emerging resistance and screen
rapidly for colonization, that risk factors for emergence be
assessed, and that health-care facilities have access to
microbiologic and epidemiologic assistance and have the
capacities for efficient isolation precautions (e.g., private
rooms with handwashing facilities, availability of gloves).
Therefore, to coordinate the timely international scientific
and public health response to emerging antimicrobial
resistance, we designed an early warning system to monitor,
analyze, control, and prevent important events in the
emergence of antimicrobial resistance at both the global and
regional or local levels. Overall, this early warning system
should trigger early epidemiologic and microbiologic
interventions to assess risk factors for emerging antimicro-
bial resistance, leading to more effective control.
Global Sentinel Events
The need to be aware of global sentinel events is leading
to an important function of the program: the periodic
publication of what INSPEAR members determine by
consensus to be important types of antimicrobial resistance
heretofore undescribed or of great public health importance
(Table 1). Criteria used to arrive at this list included the
overall ease of use of the list by most clinical and reference
Table 1. Early warning system: global sentinel events
Microorganism Resistance
Streptococcus spp. Penicillinase, gentamicin,
  glycopeptides, fluoroquinolones
S. pneumoniae Vancomycin, third-generation
  cephalosporins, new
  fluoroquinolones (gemifloxacine,
  grepafloxacin, levofloxacin,
  trovafloxacin)
Staphylococcus spp. Glycopeptides (high level)
Enterobacteriaceae Carbapenemase
Neisseria meningitidis Penicillinase, chloramphenicol,
  cephalosporins, fluoroquinolones
Acinetobacter baumannii Carbapenemase
Salmonella typhi Third-generation cephalosporins,
  fluoroquinolones
Haemophilus influenzae Cephalosporins
Brucella spp. Tetracycline, rifampin, streptomycin
Clostridium difficile Glycopeptides
Clostridium perfringens Penicillinase321 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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laboratories and the actual and potential public health
impact of resistance events based on factors such as pathogen
virulence, frequency of infection caused by the pathogen, and
absence of other licensed antimicrobial agents for treating
infections caused by the pathogen. This list of events will be
updated regularly and will be published and disseminated to
national and international surveillance systems.
Local and Regional Sentinel Events
Local and regional sentinel events consist of the first
observation of a clinically important form of resistance in a
particular locality or region. Such resistant phenotypes may
already be well described from other localities or regions of the
world (Table 2). The new regional emergence of resistance in
an INSPEAR facility may warrant a coordinated response
from local or international INSPEAR members to prevent the
resistant strains from becoming endemic.
Functioning of the Early Warning System
The early warning system should function according to
subsidiarity, defined as the principle that a central authority
should have a subsidiary function, performing only tasks that
cannot be performed effectively at a more immediate or local
level. When an emerging event is suspected at an INSPEAR
center, the national or regional coordinator should be alerted
and microbiologic confirmation performed at the local,
national, or regional level when possible, or with additional
INSPEAR resources (Figure). Once an event is confirmed, the
INSPEAR coordinator will be informed and the public health
authorities, WHO, and the INSPEAR centers will be notified.
At the same time, an epidemiologic investigation will search
for additional cases and assess risk factors through cohort or
case-control studies, and surveillance will be implemented.
As with microbiologic support, epidemiologic investigation
will be performed at the local, national, or regional level if
possible; if necessary, INSPEAR resources will be provided.
In addition, public health authorities, WHO, and INSPEAR
centers will be notified so that measures may be immediately
implemented if such an event occurs elsewhere.
Responses to Emerging Resistance
INSPEAR response may include immediate, specific
responses, such as microbiologic support (e.g., confirmation of
resistance, studying the mechanism of resistance, molecular
typing to determine clonality) or on-site epidemiologic and
infection control support (e.g., assistance with outbreak
investigation, intervention studies, control measures) (Table
3). The level of response will be determined by local need,
importance of the problem, and capacity of INSPEAR
members to respond. In addition, the INSPEAR response to
emerging resistance will include coordination of longer term
studies to improve the methods for detection and control of
resistance. Finally, the INSPEAR response will include the
education and training of personnel at INSPEAR hospitals.
Conclusions
INSPEAR is the first international program dedicated to
the control of antimicrobial resistance that combines
microbiologic and epidemiologic expertise provided by
national reference laboratories and public health agencies.
This program should facilitate control of novel antimicrobial-
resistant pathogens at the time of their emergence and
increase the likelihood of controlling and preventing those
pathogens before they become endemic. However, as the
results of our MRSA survey and proficiency testing indicate,
the microbiologic and epidemiologic capacities of health-care
facilities worldwide will need to be strengthened if our goal of
detection and control of multidrug-resistant pathogens is to
be achieved.
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Table 2. Early warning system: local and regional sentinel events
Microorganism Resistance
Staphylococcus aureus Methicillin, intermediate
  susceptibility to glycopeptides
Enterococcus spp. Vancomycin
Enterobacteriaceae Extended-spectrum beta-
  lactamase-mediated resistance,
  carbapenems, fluoroquinolones
Acinetobacter baumannii Carbapenem
Any bacteria All antimicrobials available at the
  regional and local settings
Figure. Functioning of the early warning system.
Table 3. INSPEAR resources
Microbiology                 Epidemiology
Bacterial identification Surveillance system
Antimicrobial
  Resistance, testing, Study design and conduct
    and characterization
    of mechanisms
  Typing Outbreak investigation
  Quality control programs Infection prevention interventions
  Proficiency testing Statistical analysis
  Training Statistical training322 Emerging Infectious Diseases Vol. 7, No. 2, March–April 2001
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